Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2020

View Archived Issues

IRDye800CW-nimotuzumab enters phase I/II study for image-guided lung cancer surgery

Q32 Bio begins phase I study with ADX-914 in healthy volunteers

Regeneron initiates phase I study of NPR1 agonist REGN-5381

Prion protein's positive point

"Fight or flight" nervous system helps fight tumors, too

Preliminary results support ongoing development of Biogen's BTK inhibitor

Dosing starts in phase I study of exoIL-12

EMA approves label update for HyQvia

Arbutus presents continued positive data from first-in-human study of AB-729

SAB-402, a novel potent dual EGFR/HER4 tyrosine kinase inhibitor with promising activity in vivo

Specific PAC1 receptor antibody as potential new treatment of primary headaches

RNA-targeted CRISPR reverses myotonic dystrophy symptoms

Bioardis divulges new FGFR4 inhibitors

C4 Therapeutics patents new CRBN-targeting compounds

Bristol-Myers Squibb identifies TYK2 inhibitors

FDA clears IND for bispecific antibody EMB-02 for solid tumors

AC Immune identifies new MAPT aggregation inhibitors

Sec61 protein secretion-interfering compounds presented by Kezar Life Sciences

New animal model created to study cerebellar dysfunction in multiple sclerosis

Phase III trial of ganaxolone in CDKL5 deficiency disorder meets primary endpoint

AQP4 and Cx43 expression alteration leads to neuromyelitis optica

Escient initiates phase I/Ib study of EP-547 to treat cholestatic and uremic pruritus

New preclinical data reported on ICON-2 for solid tumors

Grant supports Melior's evaluation of tolimidone for COVID-19

Innovation Pharmaceuticals reports new in vitro data on use of brilacidin for COVID-19

Lilly reports interim phase II data on SARS-CoV-2 neutralizing antibody LY-CoV555

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...